IM Cannabis Faces Nasdaq Delisting Threat Amid Market Headwinds

TORONTO, ON – April 10, 2026 – IM Cannabis Corp. (Nasdaq: IMCC), an international medical cannabis firm with operations in Israel and Germany, is now on the clock. The company confirmed today it has received a formal notice from Nasdaq for failing to meet the exchange's minimum bid price requirement, a development that puts its prestigious listing in jeopardy and casts a spotlight on the persistent volatility plaguing the global cannabis industry.

According to the notice, IMCC's common shares have traded below the mandatory $1.00 threshold for an extended period, triggering a potential delisting process. The company has been granted an initial 180-day grace period, until October 6, 2026, to regain compliance. For now, the notice has no immediate effect, and the company's shares will continue to trade on the Nasdaq Capital Market under the symbol 'IMCC'.

However, the path back to good standing is steep. To satisfy Nasdaq's rule, IMCC's closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days before the October deadline. Failure to do so could lead to its removal from the exchange, a move with severe consequences for liquidity and investor confidence.

A Ticking Clock on a Volatile Exchange

The Nasdaq notice did not come out of the blue. An analysis of IM Cannabis Corp.'s stock performance reveals a precipitous decline over the past year. As of April 8, 2026, the stock closed at a mere $0.34, a staggering 74% drop from its price of $1.32 just one year prior. The company's 52-week trading range, which spans from a low of $0.295 to a high of $7.12, illustrates the extreme volatility and the sharp, sustained downturn that ultimately led to its current predicament.

In its official statement, the company affirmed that maintaining its Nasdaq listing is a priority and that it is monitoring the situation closely. While IMCC stated it “intends to consider available options to cure the deficiency,” it did not specify what those options might be. Companies in this situation often turn to a reverse stock split, a corporate action that consolidates existing shares to artificially inflate the per-share price. While effective in the short term for meeting exchange requirements, analysts often view this move with skepticism, as it fails to address the underlying business fundamentals that caused the price drop in the first place.

Should the company fail to regain compliance by October, it may be eligible for a second 180-day period, provided it meets all other Nasdaq listing standards. However, if it cannot right the ship within the allotted time, Nasdaq will issue a delisting determination, forcing the stock onto less liquid over-the-counter (OTC) markets.

A Tale of Two Markets: German Growth vs. Sector Headwinds

Beneath the alarming stock chart lies a more complex financial picture. The company's full-year 2025 results, released on March 31, 2026, show a business grappling with market challenges but also demonstrating pockets of significant strength. A key bright spot is its German operation, Adjupharm GmbH, which saw revenues surge by over 134% to $36.3 million, now accounting for two-thirds of the company's total revenue.

This growth was fueled by Germany's landmark Cannabis Act, which took effect in April 2024 and reclassified medical cannabis, slashing bureaucratic hurdles. However, the German market has since seen new regulatory headwinds. In October 2025, the government implemented stricter rules aimed at curbing the boom in telemedicine prescriptions, now prohibiting the mail-order trade of cannabis and requiring in-person physician visits for initial prescriptions. These changes could temper the explosive growth that has buoyed companies like IMCC.

Simultaneously, the company's focus on the Israeli market presents its own set of challenges. Despite recent regulatory reforms designed to streamline patient access, Israel's medical cannabis market has seen a surprising 7.5% decline in active licenses between January 2024 and March 2025. The difficult operating environment has caused some firms to exit the market entirely, making IMCC's strategic pivot to focus resources there a calculated risk.

Financially, the company achieved a major milestone in 2025 by generating positive cash flow from operating activities for the first time in its recent history. Yet, it still posted a net loss of $5.9 million for the year and missed analyst revenue and earnings estimates for the fourth quarter, signals that continue to weigh on investor sentiment.

The High Stakes of Delisting

IMCC's struggle is emblematic of a broader malaise affecting the cannabis sector. Despite growing legalization and market size projections, the industry remains hampered by inconsistent regulations, banking restrictions, and weak investor confidence. Many cannabis stocks have been battered, and IMCC is far from the only company facing pressure from exchanges.

For IM Cannabis, the stakes could not be higher. A delisting from Nasdaq would likely trigger a cascade of negative consequences. Trading would move to the OTC markets, where liquidity is far lower, making it more difficult for shareholders to buy or sell stock. Many institutional investors, such as pension funds and mutual funds, are prohibited by their charters from holding OTC stocks, which could lead to forced selling and further downward pressure on the share price.

Furthermore, delisting severely curtails a company's ability to raise capital for future growth, a critical issue for any firm in a capital-intensive industry. It also carries significant reputational damage, signaling to the market a failure to maintain the standards of a major U.S. exchange.

In what could be interpreted as a move to diversify and create shareholder value, IMCC announced in March a non-binding agreement to acquire a majority stake in Blackaxe Technologies, a firm specializing in cyber drone interception and satellite intelligence. Whether such strategic pivots, combined with operational discipline in its core cannabis business, will be enough to win back investor confidence and push its stock back over the $1.00 threshold before the clock runs out remains the critical question.